Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study | BMC Cancer | Full Text

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study | BMC Cancer | Full Text

Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study

NEPA is an oral fixed-dose combination of netupitant, a new highly selective neurokinin-1 receptor antagonist, and palonosetron. This study was conducted to evaluate whether the efficacy of NEPA against chemot...

Authors:Roberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, Rosalba Torrisi, Ida Paris, Monica Giordano, Vincenzo Montesarchio, Valentina Guarneri, Laura Amaducci, Domenico Bilancia, Giuseppina Cilenti, Alessandra Fabi, Elena Collovà, Alessio Schirone, Erminio Bonizzoni, Luigi Celio…

Citation:BMC Cancer 2020 20:232

Content type:Research article

Published on: 19 March 2020

• ViewFull Text
 
• ViewPDF